Amyloid-Lowering Agents
Monoclonal Antibodies
BACE1 Inhibitors
Gamma-secretase Inhibitors
Immunotherapy
Aggregation Inhibitors
Aducanumab
Lecanemab
binds to aggregated AB
binds to amyloid fibrils
(prevents aggregation)
Active immunisation
Passive immunisation
vaccines
exogenous antibodies
Prevents cleaving of APP
prevent monomers from becoming oligomers
Limitations
Efficacy challenges
(especially in late-stage AD)
ARIA
(edema/hemorrhages in MRI)
intervention must be early
Expensive
References
Cummings 2023